intelliheart set for european distribution

ASX Announcement
17 September 2007
INTELLIHEART SET FOR EUROPEAN DISTRIBUTION
IM Medical Limited (ASX: IMI) announces today that it is now able to commence
discussions on distribution of its Intelliheart diagnostic system into Europe.
The Intelliheart system, including its software, is on the Australian Register of Therapeutic
Goods.
Under European law, the Australian approvals mean that IM Medical’s European
representative will be able to distribute the product in accordance with Article 12 and
Annex VII of the Medical Device Directives (93/42/EEC).
The European distribution move is part of the company’s strategy to expand into overseas
markets with Intelliheart and IM Medical’s new Cardanal technology.
Intelliheart uses a series of tests to assess cardiac risk. The Cardanal technology is being
integrated into Intelliheart to provide cardiologists with faster and more reliable tools to
diagnose heart conditions.
A separate application for Cardanal is the facility to transmit high-quality data in the form
of ECG waves over the Internet in real time, clearing the way for remote diagnosis of heart
problems.
The Cardanal technology will be marketed worldwide, with an initial focus on hospitals
and specialist medical practices.
Enquiries: Tommas Bonvino, CEO (03) 9860 0900
Media enquiries: Michael Smith 0411 055 306